DocDollars

Ivoclar Vivadent, Inc.

NY · United States · Reporting entity ID 100000010562

Total reported 2019–2025
$3.12M
#873 of 2,960 reporting companies — 0% of all reported industry payments
$2.20M in general payments across 6,130 records, plus $918K in research funding across 152 records.

How it breaks down

General payments $2,197,582
Research funding $918,414

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ivoclar Vivadent, Inc. reported $3.12M to US doctors and teaching hospitals from 2019 to 2025, ranking #873 of 2,960 reporting companies. 29% of that was research funding and 71% general payments such as consulting, speaking, food and travel. 6,130 general payment records and 152 research records were filed.

Common questions about Ivoclar Vivadent, Inc.

How much has Ivoclar Vivadent, Inc. paid US doctors?

Ivoclar Vivadent, Inc. reported $3,115,996 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,197,582 in general payments, $918,414 in research funding.

How does Ivoclar Vivadent, Inc. rank among drug and device companies?

It ranks #873 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Ivoclar Vivadent, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.